Detection of a neoantigen on human C3bi and C3d by monoclonal antibody.
A neoantigen was detected on human C3bi and C3d by using the monoclonal antibody (MoAb) 130. The antibody bound to EC3bi and EC3d cells but not to EC3b. Although highly purified C3bi or C3d strongly inhibited the binding of the antibody to EC3d, highly purified C3c had no such effect. Native C3, C3b, or C3(H2O) inhibited this binding only weakly. The neoantigen was also detected in serum after activation with zymosan or heat-aggregated IgG, and it was found bound to the aggregated IgG and zymosan particles. Plasma samples from patients with immunologic disorders were tested for this neoantigen, and 25 out of 43 samples tested were found to have levels of neoantigen corresponding to 2 to 11.5% complement activation, whereas 13 out of 14 normal donor plasmas contained amounts of neoantigen indicating much less than 1% complement activation.
Tamerius
J D
JD
Pangburn
M K
MK
Müller-Eberhard
H J
HJ
D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D000936:Antigen-Antibody Complex; D001172:Arthritis, Rheumatoid / Q000276:immunology; D001327:Autoimmune Diseases / Q000276:immunology; D003167:Complement Activation; D003176:Complement C3 / Q000276:immunology*; D003179:Complement C3b / Q000276:immunology*; D015933:Complement C3d; D000939:Epitopes; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000276:immunology; D015054:Zymosan / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; D003176:Complement C3; D000939:Epitopes; D003179:Complement C3b; D015933:Complement C3d; D015054:Zymosan